The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC), are seeking proposals for Small Business Innovation Research (SBIR) contracts. The solicitation, titled "Microbiome-Based Tests for Cancer Research, Diagnosis, Prognosis and/or Patient Management," focuses on the development of microbiome-based technologies for cancer research and patient management. The goal is to improve early and accurate diagnosis, prognosis, treatment assignment, and efficacy monitoring for various types of cancer. The solicitation emphasizes the need for technologies that address the limitations of current diagnostic tests, such as high false positive rates and low sensitivity. The proposed technologies should ideally use liquid biopsies, which are safer, more cost-effective, and faster to obtain than solid biopsies. The development of microbial signatures from cancer patient samples, in combination with other biomarkers, offers an exciting opportunity to develop new tools for better cancer diagnosis, prognosis, and patient management. The solicitation anticipates awarding 4-6 contracts, with a budget of up to $400,000 for Phase I projects lasting up to 12 months, and up to $2,000,000 for Phase II projects lasting up to 2 years. Proposals that exceed the specified budget or project duration may not be funded. The solicitation is closed, with a release date of August 25, 2023, and a closing date of November 14, 2023. More information can be found on the grants.gov website.